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 Abstract  
The interleukin-6 (IL-6) family of cytokines consists of IL-6, IL-11, IL-27, IL-31, oncostatin M 
(OSM), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin-1 
(CT-1), and cardiotrophin-like cytokine factor 1 (CLCF1). Membership of this cytokine family is 
defined by usage of common β-receptor signalling subunits, which activate various intracellular 
signalling pathways. Each IL-6 family member elicits responses essential to the physiological 
control of immune homeostasis, haematopoiesis, inflammation, development and metabolism. 
Accordingly, distortion of these cytokine activities often promotes chronic disease and cancer; 
the pathological significance of this is exemplified by the successful treatment of certain 
autoimmune conditions with drugs that target the IL-6 pathway. Here, we discuss the emerging 
roles for IL-6 family members in infection, chronic inflammation, autoimmunity and cancer, and 
review therapeutic strategies designed to manipulate these cytokines in disease.  
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[H1] Introduction 
Cytokines contribute to all aspects of human biology and have evolved to enable the sensing 
and interpretation of environmental cues relevant to the maintenance of normal host 
physiology1. Although these secretory proteins are best known for their role as custodians of 
immune homeostasis and the inflammatory response to infection, trauma or injury, their 
diverse functions also affect embryonic development, cognitive function and behaviour, tissue 
integrity, and ageing. In this regard, cytokines often display pleiotropic or overlapping functional 
properties1. 
The interleukin-6 (IL-6) cytokine family comprises IL-6, IL-11, IL-27, IL-31, oncostatin M 
(OSM), leukemia inhibitory factor (LIF), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1)  
and cardiotrophin-like cytokine factor 1 (CLCF1), and among all cytokine families it arguably 
displays the highest degree of functional pleiotropy and redundancy in eliciting responses 
relevant to health and disease2. Members of this family play prominent roles in chronic 
inflammation, autoimmunity, infectious disease and cancer (BOX 1), where they often act as 
diagnostic or prognostic indicators of disease activity and response to therapy1,3-6. Moreover, 
IL-6 family cytokines are now viewed as major therapeutic targets for clinical intervention3-9. 
This is epitomized by the treatment of chronic immune-related conditions, such as inflammatory 
arthritis, giant cell arteritis and Castleman’s disease, with drugs that target IL-65,10-12. In this 
Review, we will draw on recent advances to provide a timely update on the biology of IL-6 
family cytokines and their clinical potential as therapeutic targets or disease modifiers in 
autoimmunity, inflammation, infection and cancer. 
 
[H1] What constitutes IL-6 family membership? 
IL-6 remains the archetypal member of the IL-6 cytokine family, and regulates a diverse array of 
functions relevant to haematopoiesis, tissue homeostasis, metabolism and immunity (BOX 1 & 
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BOX 2)5,13. Since the discovery of IL-6, subsequent investigations have revealed a high degree of 
functional redundancy amongst IL-6 family cytokines14. As a consequence, cytokines within this 
family are often described with activities attributed to lymphokines [G], adipokines [G] or 
myokines [G], which reflect their broad expression and cellular distribution among all major cell 
types within the body. This redundancy is characterized by a precise hierarchical involvement in 
inflammation, metabolism, development, tissue regeneration, neurogenesis and oncogenesis 
(BOX 1 & BOX 2)15.  
A defining feature of this cytokine family is its usage of common cytokine receptor 
subunits. These receptor complexes comprise the shared signal-transducing receptor β-subunit, 
glycoprotein 130kDa (gp130), together with either a ligand-binding non-signalling receptor 
α-subunit or a signalling receptor β-subunit that resembles gp1302,15,16 (FIG. 1). The receptor 
signalling complexes for IL-6 and IL-11 contain a gp130 homodimer, whereas other family 
members signal via a heterodimeric receptor complex containing gp130 and an alternative 
signalling β-subunit (FIG. 1). The exception to this ‘gp130 rule’ is IL-31, which binds a cytokine 
receptor complex containing the OSM receptor β-subunit (OSMR) and a cognate IL-31-binding 
receptor termed cytokine-binding gp130-like protein (GPL, also known as IL-31RA)17-19.  
Phylogenetic analysis of cytokine families reveals that members of the IL-6 family share a 
close relationship with IL-12 family cytokines20-22. This link is illustrated by the heterodimeric 
composition of IL-27 (comprising IL-27p28 (also termed IL-30) and Epstein-Barr virus-induced 
protein-3; EBI3), which is structurally related to the IL-12 (IL-12p40–IL-12p35), IL-23 (IL-23p19–
IL-12p40), IL-35 (IL-12p40–EBI3), and IL-39 (IL-23p19–EBI3) heterodimers23-25. Interestingly, both 
IL-27p28 and IL-35 can also signal via gp13026,27, although the biological significance of this 
engagement with gp130 requires further substantiation, and thus their membership to the IL-6 
family of cytokine is premature. 
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The functional diversity and redundancy associated with IL-6 family cytokines is partially 
explained by the presence of the ubiquitously expressed common gp130 signal-transducing 
receptor (FIG. 1). Use of the common gp130 receptor subunit contributes to the regulation of a 
wide range of overlapping activities that are controlled by IL-6 family cytokines. As a 
consequence, these cytokines play key roles in many physiological processes, including 
development, as evidenced by the embryonic lethality of gp130-deficient mice28. In contrast to 
gp130, the receptor subunits specific to individual family members display a more restricted 
cellular expression profile, and the phenotype of mice lacking individual cytokine family 
members or their associated receptor subunits is often less severe than their apparent 
pleiotropic properties would suggest28,30,76,91.  
While the tissue distribution of these receptors offers some distinction as to how 
individual family members act in defined cellular compartments, certain cytokines within the 
family have evolved several mechanisms that amplify or broaden their cellular activities. For 
example, human OSM can signal via gp130–LIFR or gp130–OSMR receptor complexes to 
mediate responses typically associated with LIF (for example, haematopoiesis)17. Receptor 
promiscuity can also elicit defined forms of cytokine receptor crosstalk. For instance, CNTF 
displays a low affinity interaction with IL-6Rα that can lead to the formation and activation of an 
IL-6Rα–gp130–LIFR signalling receptor complex2,31. Such cross-regulation may afford CNTF the 
capacity to control IL-6-related processes not normally associated with its primary involvement 
in the nervous system (for example, metabolism, bone remodelling, immune regulation) (BOX 1 
& BOX 2)32,33. The complexities of IL-6Rα usage also extend to cytokines beyond the IL-6 
cytokine family, with a recent example being IL-27p28, which moderates inflammatory activities 
through engagement of an IL-6Rα–gp130 receptor system27,34,35.  
In addition to these ‘classical’ mechanisms of cytokine receptor signalling, several 
members of the IL-6 family employ alternative modes of gp130 activation termed ‘cytokine 
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trans-signalling’ (relevant to IL-6, IL-11, CNTF) and ‘trans-presentation’ (relevant to IL-6) (BOX 3). 
These alternative modes of cytokine signalling are best epitomized by the action of IL-6, and we 
refer the reader to several recent articles that review the regulation and biological properties of 
classical IL-6 receptor signalling and IL-6 trans-signalling in health and disease5,15,17,29,36-38. 
Briefly, classical IL-6 receptor signalling describes activities mediated via the membrane-bound 
IL-6 receptor complex, and is restricted to cells that express both IL-6Rα and gp13029. In 
contrast, IL-6 trans-signalling denotes a process that involves IL-6 binding to a soluble form of 
IL-6Rα (sIL-6R), which maintains the circulating half-life of IL-6, and enhances its 
bioavailability39,40. Interestingly, sIL-6R shares sequence identity with both IL-12p40 and EBI3, 
and once bound with IL-6 resembles a heterodimeric cytokine similar to IL-12-related 
cytokines5,20,41. In this regard, the IL-6:sIL-6R complex is able to directly engage and activate 
membrane-bound gp130 to facilitate IL-6 signalling in cell types that would not normally 
respond to IL-629. Thus, trans-signalling serves to broaden the target cell repertoire of IL-6, and 
is considered the primary mechanism for IL-6 involvement in numerous chronic diseases and 
cancers5,29,37. Intriguingly, similar cytokine trans-signalling mechanisms have been described for 
IL-11 and CNTF, and recent in vitro observations infer that both IL-27p28 and EBI3 can also 
induce sIL-6R-mediated forms of trans-signalling (BOX 3)2,15,35,42-44. While the in vivo 
consequences of these latter signalling modes require further evaluation, the identification of 
soluble variants of gp130 (sgp130) in human serum, urine and inflammatory exudates that 
antagonize both IL-6 and IL-11 trans-signalling emphasizes the biological significance of these 
alternative signalling mechanisms17,29,38,44.  
 
[H1] Regulation of intracellular signalling  
All IL-6-related cytokine receptor complexes transduce intracellular signals via the Janus kinase 
(JAK) – signal transducer and activator of transcription (STAT) pathway [G], where receptor-
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associated JAKs (namely, JAK1, JAK2 and TYK2) activate the latent transcription factors STAT1, 
STAT3 and (to a lesser extent) STAT5 (BOX 1)6,9,16. Other signalling intermediates activated in 
response to IL-6 family cytokines include: first, the protein tyrosine phosphatase SHP2 (also 
known as PTPN11), which promotes activation of the RAS–RAF–extracellular signal-regulated 
kinase 1 (ERK1)/ERK2 mitogen-activated protein kinase (MAPK) and phosphotidylinositol-3-
kinase (PI3K)–protein kinase B (PKB, also known as AKT) pathways; and second, the 
transcription factor CAAT-enhancer binding protein β (C/EBPβ, also known as NF-IL-6) (BOX 1)16. 
Recently, IL-6- and IL-11-induced activation of PI3K was shown to regulate the mTOR complex 1 
(mTORC1) system, which controls telomerase activity and protein synthesis, and influences 
various cellular processes including metabolism and redox stress (BOX 1)45,46. The diverse 
signalling networks activated by IL-6 also extend to Notch and Yes-associated protein (YAP), 
which upon gp130–SRC kinase-dependent activation facilitate epithelial cell proliferation and 
tissue remodelling or regeneration (BOX 1)47. 
The pathophysiological consequences of dysregulated gp130 activation on immune 
homeostasis and susceptibility to infection, autoimmunity or cancer have been widely reported, 
thus highlighting the importance of restricting the magnitude or duration of IL-6 cytokine family 
signalling in disease48-52. In this respect, multiple negative-regulatory mechanisms have evolved 
to curtail gp130-dependent signalling. These include receptor internalization, deactivation of 
receptors and signalling intermediates by protein tyrosine phosphatases, microRNA (miR)-
mediated translational repression and degradation of target mRNAs encoding cytokines or their 
receptors, and the STAT-driven induction of protein inhibitors of activated STAT (PIAS) and 
suppressor of cytokine signalling (SOCS) factors9,16,53,54. Among these, SOCS3 plays the 
predominant negative regulatory role via inhibition of JAK-STAT3 activation, and targeting 
cytokine receptor complexes for proteasome degradation53. 
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Considering the global cellular processes activated by the above signalling cascades, it is 
not surprising that IL-6 family cytokines display widespread functional pleiotropy (BOX 1). So, 
how do individual family members acquire unique biological specificity? Early investigations of 
STAT factors and their interaction with the genome provided evidence of cooperative 
mechanisms with other transcription factors, competition for overlapping transcription factor 
binding sites in gene promoter regions, and interaction with other transcriptional co-activators 
or co-repressors9,53,55. For example, the STAT3-mediated transcriptional output of IL-6 family 
cytokines can be influenced by the interaction of STAT3 with co-activators (such as p300–CBP) 
and other transcription factors, including nuclear factor-κB (NF-κB). NF-κB complexes with 
STAT3 in an unphosphorylated state to drive a distinct transcriptional signature enriched for 
genes involved in oncogenic and immune responses56-59. Interestingly, there is also an 
alternative mode of transcriptional control employed by STAT3. This occurs downstream of IL-6 
and IL-11 and involves the induction of specific miRs implicated in tumourigenesis and 
epithelial–mesenchymal transition (for example, miR-21 and miR-200 family members)60,61. 
Another mechanism by which individual IL-6 family members achieve biological specificity 
involves cross-regulation between individual STAT proteins9,62-65. For example, in cells lacking 
STAT1, STAT1-activating cytokines (for instance IFNγ) show enhanced STAT3-type responses, 
such as increased cell survival, proliferation and induction of immune tolerance. Conversely, in 
STAT3-deficient cells, IL-6 induces STAT1-associated cellular effects, such as inhibition of cell 
proliferation, induction of apoptosis and promotion of anti-tumour immunity9,63,65. Notably, a 
series of studies investigating the differential transcriptional responsiveness of T cells to IL-6 and 
IL-27 has uncovered novel insights into how cross-regulation between STAT1, STAT3 and STAT5 
can determine the effector characteristics of CD4+ T helper cells9,66,67. Specifically, while both 
cytokines transcriptionally regulate a comparable number of genes, a small number of 
immunoregulatory genes were differentially expressed (for example, Ifng, Ccl5 and Rorc), which 
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reflect the opposing pro-inflammatory and immunosuppressive functions assigned to IL-6 and 
IL-2767. In this setting, STAT3 provided the bulk of the overall transcriptional responsiveness to 
each cytokine, while STAT1 shaped the transcriptional programme specific to either IL-6 or 
IL-27.  
 
[H1] Critical modulators of innate immunity 
During inflammation, IL-6 family cytokines regulate innate immunity through direct effects on 
innate immune cells, and indirectly via activation of stromal tissue cells resident to the site of 
inflammation (BOX 1). These activities influence changes in leukocyte recruitment, their 
functional activation, differentiation and survival, and the development of a more sustained 
adaptive immune response5,15,17,68. Importantly, such roles illustrate why therapeutic targeting 
of IL-6 family members has been often associated with clinical benefit in inflammatory diseases, 
where these processes are distorted or skewed.  
The capacity of IL-6 family cytokines to regulate almost every aspect of the innate immune 
system is facilitated, at least in part, by their signalling interplay with the complement system 
and pattern recognition receptors [G]69,70. For example, IL-6 receptor, complement component 
C5a receptor and Toll-like receptor 4 (TLR4) signalling share a complex interaction that is 
relevant to the control of bacteraemia and sepsis71-73. Such interactions may include the 
collaborative crosstalk that exists between STAT3 and NF-κB74,75. Thus, IL-6 and other IL-6-
related cytokines often work in association with innate sensing systems to link innate and 
adaptive immunity, and to control anti-microbial defense. 
Studies on IL-6, IL-27, OSM and LIF highlight important roles for these cytokines in anti-
microbial and anti-viral immunity, where they provide tissue protection from infection-related 
injury68,71,76-79. These cytokines often control the recruitment, adhesion, survival and effector 
activities of neutrophils, tissue-resident and inflammatory monocytes, and innate lymphoid cell 
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populations (for example, natural killer (NK) cells). Specifically, these activities include the 
regulation of neutrophil-activating chemokines (for example, CXC-chemokine ligand 1 (CXCL1), 
CXCL5, CXCL6 and CXCL8), adhesion molecules (for example, intracellular adhesion molecule 1 
(ICAM1), vascular cell adhesion molecule 1 (VCAM1) and L-selectin) and apoptotic regulators 
(for example, B cell lymphoma 2 (BCL-2) and BCL-XL)37,80. In this regard, several in vivo studies 
have shown that IL-6 family cytokines affect the accumulation of specific immune cell subsets 
within inflamed tissues81-84. For instance, IL-6 deficiency leads to prolonged neutrophil 
infiltration at sites of infection85. Neutrophil function is, however, impaired in Il6-/- mice infected 
with Candida albicans, which may account for the loss of infection control and enhanced 
dissemination of the pathogen in these mice86. Interestingly, these activities are not directly 
governed by IL-6 acting on the neutrophil infiltrate. Instead, neutrophil phagocytosis and killing 
is controlled by inflammatory mediators released by stromal tissue cells, such as endothelial, 
smooth muscle, epithelial and mesothelial cells and fibroblasts, in response to IL-6 trans-
signalling37. In this scenario, the local regulation of IL-6 trans-signalling is reliant on the initial 
neutrophil infiltrate, which secretes sIL-6R within the inflamed tissue as a response to specific 
stimuli (for example, C-reactive protein, inflammatory chemokines, complement components, 
bioactive lipids, N-formyl peptides)5,37. Thus, sIL-6R is an alarmin that affects innate and 
adaptive immune outcomes29,37. The importance of this form of IL-6 regulation is exemplified by 
individuals carrying a specific IL6R polymorphic mutation (rs2228145)5,29,87,88. These individuals 
display heightened levels of circulating sIL-6R and this is associated with reduced markers of 
systemic inflammation and lower risk of coronary heart disease89,90. While these findings appear 
counterintuitive given the proposed importance of IL-6 trans-signalling in chronic and 
autoimmune disease, one must consider the wider properties of a soluble cytokine 
receptor17,29,38. These include maintaining the circulating half-life of the cytokine. In this context, 
the heightened sIL-6R levels complex with IL-6 and increase the bioavailability of the IL-6–sIL-6R 
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complex for antagonism by sgp130 to impair IL-6 signalling capacity17,29,38. 
What of the other IL-6-related cytokines? While the phenotypic characteristics of mice 
lacking IL-6, IL-11, LIF or CNTF reveal a degree of functional redundancy28,30,76,91, individual 
cytokines sit within a defined hierarchy. For example, in models of autoimmunity (such as 
inflammatory arthritis), Il6-/- and Il6ra-/- mice are protected, whereas Il11ra-/- and Osmrb-/- mice 
develop a disease severity comparable to wild-type mice92. Instead, Il11ra-/- and Osmrb-/- mice 
display other aspects of pathology, including impaired hepatocyte proliferation, altered bone 
turnover and monocytic cell trafficking, thymic hyperplasia and glomerulonephritis93-96. These 
studies illustrate the involvement of IL-6-related cytokines in immune homeostasis and innate 
immune activation, and emphasize the context-dependent nature of their activities. 
Understanding these subtle differences and their biology is essential when considering the 
design or clinical application of therapeutic interventions that target members of the IL-6-
related family.  
 
[H1] Orchestrators of adaptive immunity 
The regulatory capacity of IL-6-related cytokines in adaptive immunity is defined by their effects 
on the maturation of B cells into antibody-secreting cells, the survival and maintenance of long-
lived plasma cells, and the generation of lymphocytes with defined phenotypic or effector 
characteristics. While these activities often rely on the prior activation of innate immune 
responses in monocytes and specialized antigen-presenting cells, several IL-6 family cytokines 
(for example, IL-6 and IL-27) also act as lymphokines of adaptive immunity (BOX 1). For instance, 
IL-6 controls the effector characteristics of various CD4+ T helper (Th) cell populations, with 
initial investigations showed that IL-27 instructs Th1 cell development and promotes expression 
of IFNγ, the Th1 cell transcriptional regulator T-bet, STAT1 and IL-12Rβ25,23,68,97. The role of IL-27 
has since been broadened to include negative regulation of IL-2 signalling and restricting the 
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development of immune responses through the expansion of T-bet+CXCR3+ regulatory T (Treg) 
cell populations in Th1-cell mediated models of inflammation (such as acute Listeria 
monocytogenes infection)98-104. Thus, IL-27 is often protective in mouse models of chronic 
infection (for example, leishmaniasis and toxoplasmosis) and autoimmunity (for example, 
inflammatory arthritis, chronic inflammation of the central nervous system), and Il27ra-/- mice 
typically develop heightened or adverse T cell-mediated disease23,68. In contrast, IL-6 drives 
tissue-specific pathology and fibrosis through the expansion of IFNγ-secreting Th1 cells105. 
Interestingly, IL-6 does not directly promote the differentiation of Th1 or Th2 cells from naive 
CD4+ T cells, but instead controls the survival of these cells by supporting the action of other 
lymphokines5. Moreover, IL-6 acts as a cytokine commitment signal for the expansion of 
effector T cell populations, including Th17 and Th22 cells5. Regarding the former, IL-6 together 
with IL-1β, transforming growth factor β (TGFβ), IL-21 and IL-23 controls the expression of Th17 
cell-associated gene signatures (for example, genes encoding IL-17A, IL-17F, IL-22, RORγt and 
the aryl hydrocarbon receptor; AhR)5. Th17 cells play vital roles in maintaining mucosal barrier 
integrity and immunity, protection against fungal infections, and in the development of 
inflammation-associated tissue damage, and may reflect the contribution of IL-6 in maintaining 
tissue integrity and immune homeostasis at barrier surfaces106-108. Conversely, IL-27 acts as a 
negative regulator of certain effector characteristics and inhibits the generation of Th17 cells 
through the actions of STAT168,103,109. A similar interaction may also apply to IL-11 and OSM, 
which have been reported to drive or inhibit Th17 development, respectively110,111. However, it 
is unclear whether these alternative roles of IL-11 and OSM control the expansion of Th17 cell 
populations in draining lymph nodes or affect the maintenance of pathogenic effector T cells in 
inflamed tissues. 
 As discussed earlier, the contrasting lymphokine properties of IL-6 and IL-27 are primarily 
controlled by subtleties in the regulation of STAT1 and STAT3112. Among IL-6 family cytokines, 
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only IL-27 preferentially activates STAT1, and this IL-27–STAT1 axis often inhibits the IL-6-
mediated control of STAT3 to alter the effector or regulatory characteristics of T cell subsets97. 
This is exemplified by the ability of IL-27 to block the commitment towards Th17 cells through 
STAT1 control of STAT3 signalling67,113-116. This inhibitory signal is lost in STAT1-deficient T-cells, 
where IL-27 switches to promote expansion of Th17 cell populations via STAT367,113. Thus, 
alterations in the balance of cytokine-driven STAT1 and STAT3 signalling may yield distinct 
biological outcomes, which will shape the pattern of adaptive immunity controlled by IL-6-
related cytokines. For example, while IL-6 inhibits Treg cell function and prevents the conversion 
of Th17 cells into Treg cells, IL-27 stimulates suppressive Treg cell activities that regulate the 
expression of cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 
(PD1)117-121. The challenge now is to understand how IL-6-related cytokines influence the 
pathogenesis and clinical management of disease through activation of these immunological 
outcomes.  
 
[H1] Determinants of chronic autoimmune diseases 
With impacts on stromal tissue cells, tissue-resident monocytes and activated inflammatory 
leukocytes, IL-6 family cytokines play vital roles in the initiation, maintenance and resolution of 
local and systemic inflammatory outcomes that promote tissue damage, activation of the acute 
phase response, development of autoimmune reactions, and metabolism (BOX 1 & BOX 
2)5,15,17,122-126,. As a consequence, IL-6 family cytokines play a central role in the progression of 
chronic disease and autoimmunity (BOX 1). 
 Early investigations revealed that Il6-/- mice display various immunological defects, 
including impaired humoral immunity (for example, mucosal IgA antibody responses), an 
inability to mount an effective anti-microbial host defense against bacterial, fungal and viral 
infections, and a reduced capacity for wound healing76,127,128. In experimental models of 
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autoimmune or inflammatory diseases, including inflammatory arthritis, multiple sclerosis, renal 
injury and scarring, multicentric Castlemans’s disease and plasmacytoma, Il6-/- mice display a 
highly protective phenotype, and show limited histological evidence of pathology5,129. The 
administration of blocking anti-IL-6 or anti-IL-6R antibodies, or sgp130 to wild-type mice often 
recapitulates these findings, and has supported the development of biological drugs against 
IL-65,15,29.  
 At sites of disease, members of the IL-6 cytokine family drive inflammation-induced tissue 
damage. These activities are highly context-dependent, but invariably distort the physiological 
turnover of extracellular matrix and tissue remodelling. This is particularly evident in episodes of 
fibrosis, where IL-6, IL-11, IL-31 and OSM contribute to fibrotic lesions in the liver, lung, heart, 
skin, kidney and peritoneal cavity81,105,130-134. The development of these fibrotic events typically 
involves a loss of immune homeostasis and the physiological maintenance of tissue integrity. In 
particular, fibrosis and scarring often arise from an altered expression of matrix 
metalloproteases and tissue inhibitors of matrix metalloproteases, and the regulation of 
angiogenesis and vasculopathy. Several of these outcomes involve partnerships with other pro-
fibrotic cytokines (for example, IL-4, IL-13, TGFβ, CNTF and IFNγ), and the expansion of effector 
CD4+ T cell populations that shape inflammatory activities within the stromal tissue 
compartment81,105,133,135-138. Such alterations in tissue architecture invariably lead to loss of 
tissue or organ function. For example, elevated levels of IL-6 in the urine of patients with acute 
kidney injury or mesangial proliferative glomerulonephritis is often associated with poor clinical 
outcomes139,140. These observations reflect findings from animal models where IL-6 drives renal 
inflammation, tissue damage, and increased proteinuria87. However, the role of IL-6 in kidney 
disease may also relate to a breakdown in the homeostatic contribution of IL-6 to normal kidney 
function. For example, in tubular epithelial cells, IL-6 acts to preserve renal function and prevent 
damage of the epithelial lining141. Similar scenarios are also seen in the lung and gut where IL-6 
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(via trans-signalling) juggles the balance between homeostatic control of epithelial function and 
barrier integrity, and the onset of pulmonary airway or colitis-like inflammation47,142,143.  
 In inflammatory or degenerative forms of arthritis, members of the IL-6 cytokine family 
promote synovial hyperplasia, maintenance of joint inflammation, and damage to the 
underlying cartilage and bone. These hallmarks of disease are primarily regulated by STAT3, 
whose activity is largely confined to the synovial lining and clusters of CD3+ T cells within the 
inflamed synovium7,144-147. For example, gp130 knock-in mice, which display exaggerated JAK–
STAT signalling, show worse joint pathology and heightened synovial inflammation in a model of 
arthritis114,147,148,. Indeed, a monoallelic deletion of Stat3 in these mice reduces the recruitment 
and retention of inflammatory leukocytes, improves joint pathology and decreases disease 
activity147-150. In this regard, IL-6, IL-11, IL-27, OSM and LIF have significant effects on both 
cartilage and bone erosion via their regulatory actions on bone turnover and RANKL-mediated 
osteoclastogenesis151-156. Clinical correlates and experimental studies emphasize that IL-6 trans-
signalling coordinates many of these outcomes and is an important determinant of leukocyte 
infiltration and the severity of joint destruction33,147,157-161. Consequently, IL-6 trans-signalling is 
now considered the main protagonist of local IL-6-driven pathology, and therapeutic targeting 
of this mode of IL-6 signalling in animal models of inflammatory disease frequently leads to 
improved disease outcomes5,29.  
 While STAT3 activation by IL-6 family cytokines promotes disease processes, the 
contribution of cytokine signalling through STAT1 often appears to dampen disease 
activity3,29,162-166. This is illustrated by studies in Il27ra-/- mice, which display severe tissue 
pathology in models of infection and autoimmunity97,167. Although some of these effects relate 
to the impact of IL-27 on effector T cell populations, IL-27 also directs various tissue-specific 
responses in antigen-presenting cells, innate immune cells and B cells, as well as other stromal 
cells68,97,167. One interesting feature of the tissue pathology seen in Il27ra-/- mice is the 
Jones & Jenkins, 2018 Nature Reviews Immunology 
The IL-6 cytokine family in health and disease 
 16
development of ectopic lymphoid-like structures (ELS) at sites of inflammation. These organized 
lymphoid aggregates are often seen in infection, autoimmunity and cancer, and their presence 
determines clinical outcome or response to therapy168. In synovial biopsies from rheumatoid 
arthritis patients with early or established disease, inverse correlations exist between IL-27p28 
and the development of highly organized lymphoid-rich aggregates and autoantibody 
production169. Patients with this form of lymphoid-rich synovitis typically display severe or 
rapidly progressing disease and show poor response to standard biological drugs168,170. 
Consistent with IL-27 being a negative regulator of ectopic lymphoneogenesis, this inverse 
relationship is also evident in Il27ra-/- mice where the experimental onset of inflammatory 
arthritis is associated with elevated synovial expression of various mediators implicated in 
lymphoid neogenesis, including homeostatic chemokines (for example, CXCL13, CC_chemokine 
ligand 21 (CCL21) and CCL19), pro-inflammatory cytokines (for example, IL-17 and IL-21), 
follicular dendritic cell markers (for example, CD21) and transcriptional regulators (for example, 
BCL-6)169. Although the precise mechanism of ELS inhibition by IL-27 requires further 
investigation, these clinical and experimental studies suggest a role for T follicular helper (Tfh) 
cells or specialized Th17 cells, the latter of which can promote ELS formation in inflamed tissues 
from mice with pulmonary inflammation or experimental autoimmune encephalomyelitis171,172. 
Indeed, several of the genes associated with ectopic lymphoneogenesis are regulated by STAT3 
(for example, IL21, CXCL13, Bcl6), and the action of IL-27 in this setting may influence the 
transcriptional control of Th17-like and Tfh-like cells by inflammatory cytokines such as IL-6 and 
IL-21173. 
 In summary, IL-6-related cytokines play crucial roles in the orchestration of inflammatory 
processes relevant to the initiation, progression and diversity of disease activities seen in 
autoimmune and inflammatory diseases (BOX 1). As discussed in the next section, many of 
these responses are relevant to cancer, and influence both the pattern of tumour-associated 
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inflammation and the proliferative expansion or tissue invasion of cancerous cells. 
 
[H1] Contrasting roles in cancer  
Dysregulated IL-6 family cytokine expression or downstream receptor signalling are frequent 
events in cancer and are often associated with poor clinical outcomes4,174-177. In this regard, the 
pro-tumourigenic actions of IL-6 cytokine family members are elicited by both direct intrinsic 
effects on cancer cell activities (for example, cell proliferation, survival, migration, invasion and 
metastasis), and indirect effects on the stromal cell compartment, such as modulation of 
inflammation, immunosuppression and angiogenesis, which shape the local tumour 
microenvironment [G] (FIG. 2)4,174-178. Furthermore, the link between these cytokines and 
cancer extends to the recent evidence that some family members (for example, IL-6) are 
important regulators of energy metabolism (BOX 2), which is considered a hallmark feature of 
the initiation and progression of tumour growth122,123,126. Paradoxically, accumulating evidence 
suggests that some IL-6 family cytokines can also mount anti-tumour responses. The challenge, 
therefore, is to discern how the dynamic interplay between pro- and anti-tumourigenic 
activities arises in different tissue compartments, and how this interplay influences responses to 
biological drugs or immunotherapies that modulate cytokine activity. 
 
[H2] Tumour cell-intrinsic effects. Interleukin-6 is the prototypical pro-tumourigenic cytokine 
within the IL-6 cytokine family and regulates various STAT3-mediated oncogenic processes (FIG. 
2)6,50,69,176. For example, IL-6 potentiates the transcriptional induction of numerous molecular 
targets essential for cell cycle progression and survival (for example, cyclin D1, MYC, BCL-XL, 
survivin, miR-21), angiogenesis, and tumour invasion and metastasis (for example, hypoxia-
inducible factor 1α (HIF-1α), matrix metalloproteinase 2 (MMP-2), MMP-7, MMP-9, vascular 
endothelial growth factor (VEGF))60,61,149,174. Thus, IL-6 contributes to both the initiation and 
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rapid progression of tumourigenesis. In late stage disease, IL-6 also propagates the metastatic 
spread of invasive cancer cells by inducing transcriptional activators of epithelial–mesenchymal 
transition (EMT), such as SNAIL and TWIST179. Importantly, the growth-potentiating effects of 
IL-6 on cancer cells also extend to cancer stem cells, whose self-renewal and population 
expansion requires STAT3 in concert with stem cell transcription factors such as NANOG180. 
These interactions ultimately contribute to the progression of several multidrug resistant 
epithelial and haematologic malignancies180.  
Interleukin-11, LIF and OSM also display cancer-cell-autonomous pro-tumourigenic 
activities, many of which overlap with IL-6. For example, in cancers of the gastrointestinal tract 
and breast, IL-11 directly fuels tumour growth by inducing STAT3-regulated gene and miR 
networks that promote cell cycle progression, anti-apoptotic activities and 
angiogenesis4,177,178,181. In gastric cancer, the IL-11–STAT3 axis can promote expression of a TLR2 
innate sensing mechanism essential for gastric tumour cell proliferation and survival177. In 
addition, IL-11, LIF and OSM utilize JAK–STAT3 and PI3K–AKT–mTOR pathways to promote EMT-
associated cancer cell invasion and metastasis (including that of bone), and the self-renewal and 
expansion of cancer stem cell populations182-185. Indeed, the activation of these pathways by 
OSM and LIF often propagates resistance to targeted therapies and is relevant to both breast 
and lung cancer186,187. Although the cancer cell-intrinsic actions of CLCF1, CNTF, CT-1, IL-27 and 
IL-31 family members are less defined, emerging evidence suggests that IL-31 maybe pro-
tumourigenic in some lymphomas18. 
Despite the use of shared receptor signalling pathways, some cytokines within the IL-6 
family display opposing anti-tumour effects on cancer cells. For instance, in a PTEN-deficient 
prostate cancer model, IL-6–STAT3 signalling in tumour cells protects against tumour 
progression by maintaining an intact senescence-inducing ARF–MDM2–p53 tumour suppressor 
axis188. The anti-tumour effects of this family are also illustrated by comparing the properties of 
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IL-27 and OSM in various epithelial and haematological malignancies. Here, a regulatory 
interplay exists between STAT1 and STAT3, whereby IL-27 and OSM (via STAT1) counteract 
various STAT3-driven processes linked with tumour cell survival, proliferation, metastatic 
invasion and angiogenesis189,190. This differential switch in shared signalling pathways provides 
an attractive molecular explanation for the opposing pro- and anti-tumourigenic activities of the 
broader IL-6 cytokine family. More investigations are required, however, to establish how the 
balance of STAT1 and STAT3 signalling shapes the transcriptional landscape in different stages of 
neoplastic progression, and within the tumour microenvironment.  
 
[H2] Tumour cell-extrinsic effects. The tumour microenvironment of most cancers is immune 
cell-rich and immunosuppressive, and often under the influence of the complex 
immunomodulatory actions of the IL-6 family cytokines. The nature of this milieu has placed a 
heavy emphasis on research that aims to understand how these cytokines influence cancer 
inflammation and tissue remodelling in and around the tumour site, as well as the access and 
bioactivities of anti-cancer immunotherapies. Among IL-6 family cytokines, IL-6 elicits the most 
defined impact on the tumour microenvironment by promoting chronic inflammation that 
supports tumour angiogenesis and the outgrowth of transformed cells, whilst suppressing Th1 
cell-mediated anti-tumour immunity (FIG. 2)191. These pro-tumourigenic activities impact on the 
recruitment, retention and activity of tumour-infiltrating leukocytes, and are equally diverse as 
the pleiotropic innate and adaptive immune responses mediated by IL-6 in autoimmune and 
chronic inflammatory diseases. Specifically, the pro-tumourigenic effects of IL-6 include the 
generation of pathogenic Th17 cells and myeloid-derived suppressor cells (MDSCs), the 
suppression of antigen-presenting dendritic cells and anti-tumour cytotoxic CD8+ T cells and 
Treg cell activity, and the phenotypic switching of tumour-associated macrophages from a 
tumouricidal ‘M1-type’ phenotype to an immunosuppressive ‘M2-type’ macrophage 
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phenotype191. While further research is required in this area, we expect that other members of 
the IL-6 cytokine family may elicit similar outcomes. For example, IL-11 promotes inflammation-
associated tumourigenesis in the gastrointestinal tract and shares the capacity with IL-6 to 
polarize T cells and macrophages towards a more immunosuppressive phenotype4,178,181,192. 
In addition to its effects on tumour-associated immune cells, the activities of IL-6 on 
cancer-associated fibroblasts and adipocytes have attracted considerable interest for their 
indirect tumour-promoting effects. Since the interplay between IL-6 and fibroblasts in cancer 
has been covered elsewhere193, we will summarize here the recent evidence for IL-6 being an 
adipocyte-secreted cytokine (‘adipokine’) with the potential to modulate interactions between 
inflammatory and metabolic processes intrinsic to carcinogenesis. This idea is extremely 
relevant, given the increased risk of cancer in obese individuals with metabolic disorders, which 
are associated with heightened systemic inflammation. The activities of IL-6 as an adipokine, 
however, have been largely explored in the context of the paraneoplastic syndrome of cachexia 
[G], typified by wasting of adipose and muscle tissue125. For example, in murine models of lung 
and pancreatic cancer-associated cachexia, IL-6 promotes an increase in the proportion of 
brown fat within inflamed adipose tissue. These changes lead to enhanced mitochondrial 
activity and associated systemic metabolic responses that increase energy expenditure and 
wasting125. Furthermore, the intricate interplay between IL-6-mediated suppression of tumour 
immunity and dysregulated metabolism is also observed in colorectal and pancreatic cancer 
cachexia models126. Here, tumour-derived IL-6 acts as a pivotal molecular switch between pre- 
and active cachectic states by impairing hepatic ketogenesis, which upon restricted caloric 
intake triggers a metabolic-driven cachexia that negates anti-tumour immunity126. Despite the 
functional redundancy among IL-6 family cytokines, the preponderance of evidence that IL-6 is 
the primary mediator of hepatic function, metabolism and immunity (BOX 1 & BOX 2) suggests 
that the pathologic actions of this family in cancer-associated cachexia may be restricted to IL-6.  
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In contrast to IL-6, IL-27 displays potent anti-tumour activities in the tumour 
microenvironment, which reflect the opposing actions described for these cytokines in 
autoimmune and inflammatory conditions. Studies in either Il27p28-/- or Il27ra-/- mice, or mice 
treated with recombinant protein show that IL-27 potentiates anti-tumour responses through 
effects on innate and adaptive immune cells194. These include IL-27-mediated control of anti-
tumourigenic M1-type macrophages, the suppression of MDSCs, activation of cytotoxic CD8+ T 
cells and the production of IFNγ and perforin by cytolytic NK cells and natural killer T (NKT) 
cells194. Collectively, this powerhouse of anti-tumour activity has set the stage for IL-27 to be 
developed further for potential clinical application as an anti-cancer agent. 
 
[H1] Therapeutic strategies 
Drug strategies that target IL-6 cytokine family members fall into various categories: i), blocking 
monoclonal antibodies that directly act on either the cytokine or the cytokine receptor; ii), 
recombinant cytokine regimes; iii), small molecule therapies that interfere with cytokine 
receptor signalling through gp130 and the JAK–STAT pathway (FIG. 3). While some of these 
modalities are in routine clinical practice, others remain in various stages of trial development. 
The challenge facing pharmaceutical companies is to understand the types of clinical indications 
that may benefit from these therapies, and to evaluate the best approach to target these 
inflammatory cytokines. For example, does inhibition of a cytokine, its corresponding receptor 
or mode of cytokine receptor signalling provide optimal therapeutic opportunities or clinical 
outcomes? These considerations are most pertinent considering that, as discussed previously, 
certain cytokine receptors (for example, IL-6Rα) bind to more than one cytokine2,27,31,35. Thus, 
therapeutic targeting of these receptor complexes may have wider consequences than 
inhibiting an individual cytokine. In this regard, Il6-/- and Il6ra-/- mice display phenotypic 
differences in wound healing, colitis severity, and control of glucose metabolism5. 
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The rationale for therapeutic strategies based on blocking monoclonal antibodies is best 
described for IL-6195. These originate from studies of multiple myeloma where levels of IL-6 and 
sIL-6R are indicative of tumour severity, and treatment with an anti-IL-6 monoclonal antibody 
halted tumour expansion196. Although the pharmacodynamics associated with IL-6 blockade led 
to a worrying elevation in systemic IL-6 levels197, the success of this intervention study 
nonetheless informed the design of several alternative IL-6-directed therapies. These include 
the anti-IL-6R blocking monoclonal antibodies tocilizumab and sarilumab, which are 
recommended for the treatment of inflammatory arthritis, juvenile idiopathic arthritis, adult 
onset Still’s disease, multicentric Castleman’s disease, cytokine release syndrome (including that 
associated with chimeric antigen receptor (CAR) T cell therapy) and giant cell arteritis10-12,198-202. 
In rheumatoid arthritis, tocilizumab and sarilumab are also prescribed as monotherapies for 
patients displaying an inadequate or adverse response to methotrexate3,203. 
Structure–function studies have identified amino acid motifs essential for IL-6 
engagement with IL-6R and their interaction with gp1305,204, leading to the rationale design of 
tocilizumab and sarilumab which target IL-6R, and sirukumab, siltuximab and clazakizumab that 
target IL-6 (FIG. 3)5,186. Additional biological drugs including olokizumab and EBI-031 prevent IL-6 
interaction with gp130, while olamkicept (an engineered chimeric sgp130 protein that may 
target cytokine trans-signalling by IL-6 and IL-11)44, NI-1201 (an anti-IL-6R monoclonal antibody), 
and VHH6 (junctional epitope nanobody [G] that recognizes the IL-6–IL-6R complex) selectively 
inhibit IL-6 trans-signalling5,27,44,205-207. These drugs show considerable promise in pre-clinical 
studies, early clinical trials and routine clinical practice (FIG. 3), although we note that the FDA 
has recently rejected approval of sirukumab due to safety concerns. 
Another major challenge facing pharmaceutical companies is to differentiate these drugs 
in terms of their efficacy and safety3,8. For example, clinical experience with tocilizumab therapy 
shows that patients often develop neutropenia and adverse effects, such as increased 
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infections. Although therapeutic blockade of IL-6 promotes neutropaenia, tocilizumab does not 
promote neutrophil cell death or an increase in nonphlogistic phagocytosis by monocytic 
cells208. Instead, the development of neutropaenia may reflect the role of IL-6 in controlling 
granulopoiesis209. In this regard, the incidence and type of infections associated with 
tocilizumab intervention are similar to those seen with other biological drugs. Here, infections 
typically occur at epithelial surfaces and mucosal barriers (for example, upper and lower 
respiratory tract, urinary and gastrointestinal tracts) where IL-6 ensures the maintenance of 
immune homeostasis3,8,210,211. This is reflected by the incidence of adverse bacterial infections of 
the skin that arise in response to tocilizumab treatment of atopic dermatitis210. As a 
consequence, tocilizumab therapy appears less effective in diseases where IL-6 contributes to 
epithelial homeostasis or barrier integrity5. Thus, a prior incidence of gastric perforations or 
associated diverticulitis are considered contraindications for the use of tocilizumab5,29. 
In hindsight, infections on barrier surfaces may have been predicted based on the known 
biology of IL-6 and its predominant usage of the JAK–STAT3 pathway. For example, patients 
possessing inhibitory autoantibodies against IL-6 or displaying genetic mutations within the JAK–
STAT signalling cassette frequently develop recurrent staphylococcal cellulitis and subcutaneous 
abscesses48,49,51,212. Indeed, patients with autosomal dominant hyper-immunoglobulin E 
syndrome (Job’s syndrome) that is associated with STAT3 deficiency experience recurrent 
bacterial infections of the skin and lungs, and typically suffer from eczema51. These observations 
highlight the need to predict the involvement of IL-6 in the underlining pathology using 
stratification criteria that maximize patient response rates. This is epitomized for rheumatoid 
arthritis, where despite IL-6 or IL-6R inhibition being highly efficacious, some patients still 
display an inadequate response to therapy3,7,8,203.  
Other effects associated with IL-6 blocking interventions include alterations in serum 
lipid profiles and liver transaminases213,214. With respect to the former, tocilizumab leads to 
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augmented levels of low-density and high-density lipoprotein C, as well as changes to the 
composition of cholesterol214. Furthermore, tocilizumab suppresses levels of cholesterol-
associated clinical biomarkers of cardiovascular risk, namely high-density lipoprotein-associated 
serum amyloid A, secretory phospholipase A2 and lipoprotein A215. Thus, targeting IL-6 may be 
of clinical benefit in treating cardiovascular conditions, including pulmonary arterial 
hypertension216. In this regard, the risk of cardiovascular events associated with tocilizumab is 
comparable to that seen with other agents (for example, tumour necrosis factor (TNF) 
inhibitors)217. However, tempering this notion is the recent observation that tocilizumab 
treatment of individuals with systemic vasculitis (Kawazaki’s disease) may cause increased risk 
of cardiovascular complications, such as coronary-artery aneurysms218. In addition, serious 
adverse infections (such as those associated with tocilizumab and other classes of biological 
drug therapies) can predispose individuals to myocardial infarction or stroke219. Notably, 
systemic inflammation is also commonly associated with increased risk of cardiovascular 
disease214, suggesting that biological drugs that preferentially control inflammation over lipid 
profiles may afford greater protection against cardiovascular events. For example, therapeutic 
targeting of the pro-inflammatory cytokine IL-1β with canakinumab significantly lowers the rate 
of recurrent cardiovascular events (myocardial infarction, stroke), but has a negligible effect on 
circulating lipids220. Therefore, biological drugs that preferentially target systemic inflammation 
(for example, anti-IL-1 therapy), rather than circulating lipids (for example, anti-IL-6 therapy), 
may provide a more effective cardio-protective intervention. 
As discussed earlier, IL-6 has a major influence on the proliferation, survival and 
metastatic properties of cancerous cells, and studies using preclinical mouse models indicate 
that treatments targeting IL-6 or its receptor display therapeutic efficacy as anti-cancer agents6. 
As a consequence, several phase I/II clinical trials have evaluated the therapeutic application of 
tocilizumab, clazakizumab and siltuximab in prostate, lung and breast cancer, multiple 
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myeloma, and cancer cachexia221-223. While patients have shown a poor clinical response to 
these therapies, current trials have been restricted to non-stratified patient cohorts and 
highlight the need to identify predictive biomarkers for precision medicine approaches 
incorporating IL-6-directed therapies. Despite these poor clinical outcomes, such therapies can 
be exploited in cancer to counteract adverse symptoms associated with cancer immunotherapy, 
such as hypotension, fatigue, nausea, shivering, enhanced acute phase activity. This is 
particularly evident in CAR T cell therapy, where severe fever responses, hypercytokinemia and 
life-threatening forms of ‘cytokine storm’ are controlled by treatment with tocilizumab224,225.  
In addition to IL-6, the association between OSM activity and various disease states has 
led to the development of a humanized anti-OSM monoclonal antibody (GSK315234). However, 
a phase II trial designed to examine the safety, tolerability and efficacy of GSK315234 in patients 
with active rheumatoid arthritis showed no significant improvement in disease activity226. 
Interestingly, this lack of efficacy was attributed to an inferior binding affinity and off-rate 
kinetics of GSK315234 as compared to the high-affinity interaction of OSM with its receptor. 
Therefore, future clinical trials with high-affinity anti-OSM antibodies are anticipated not only in 
rheumatoid arthritis, but also in inflammatory bowel disease patients where high OSM and 
OSMRβ expression in intestinal tissues correlate with a lack of response to anti-TNF agents227.  
The anti-inflammatory properties of IL-6 family members in numerous in vivo disease 
models have led to the design of cytokine therapies that promote the action of CNTF, LIF, IL-11 
and IL-27. For example, clinical trials have attempted to exploit the neurotrophic properties of 
CNTF in the treatment of degenerative diseases associated with the brain (for example, 
Huntington disease) and eye (for example, retinitis pigmentosa and age-related macular 
degeneration)228-230. However, adverse events including severe weight loss, hyperalgesia, 
coughing, muscle fatigue and pain have led to the suspension of these studies. Similarly, a trial 
with recombinant IL-11 in rheumatoid arthritis patients was also ineffective231. Nonetheless, 
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therapeutic strategies based on the neuroprotective properties of LIF and the anti-inflammatory 
characteristics of IL-27 may offer more promising applications in the treatment of multiple 
sclerosis, rheumatoid arthritis and other autoimmune or inflammatory diseases155,232-234.  
Several small molecule designer drugs have been developed to mimic cytokine–cytokine 
receptor engagement or to moderate gp130 receptor signalling (FIG. 3)235-238. For example, 
regulator of cartilage growth and differentiation (RCGD)-423 promotes a transient activation of 
gp130 dimerisation and signalling235. With applications in the treatment of osteoarthritis, RCGD-
423 prevents chondrocyte hypertrophy and cartilage destruction in rat models of disease and 
promotes chondrocyte proliferation and survival235. Other modalities that interfere with gp130 
signalling include madindoline-A, the small molecule inhibitor SC144, and the synthetic 
oxazolidinone derivative LMT-28236-238. While the clinical utility of these drugs requires further 
investigation, SC144 has been touted as a small molecule gp130 inhibitor for the treatment for 
ovarian cancer236.  
Another class of drug intervention, which is not selective for gp130 cytokine receptor 
signalling but has generated substantial attention over recent years, is based on blockade of the 
JAK–STAT3 axis6,9. The most advanced drugs of this type include tofacitinib, ruxolitinib, 
oclacitinib and baricitinib, which target JAK1, JAK2 or JAK3239. These JAK inhibitors are potent 
disease modifying agents and are approved or in clinical trials for the treatment of rheumatoid 
arthritis, psoriasis, myelofibrosis and other forms of autoimmune disease and cancer239. 
Similarly, various anti-sense oligonucleotide inhibitors (for example, AZD9150, which targets 
STAT3), modulators of inhibitory SOCS3 activity, natural chemical blockers of STAT3 activity (for 
example, curcumin and capsaicin) and inhibitors of STAT3 binding to DNA (for example, CPA-1, 
CPA-7) are also considered promising therapies for these diseases (FIG. 3)240-244.  
 
[H1] Concluding remarks 
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The IL-6 cytokine family is arguably the most complex group of related cytokines and affects all 
major biological systems within the body. In this respect, IL-6 family members are essential for 
development, reproduction, tissue regeneration, immune homeostasis, and defense and repair 
from infection, trauma or injury. However, their involvement in chronic disease and cancer 
identify them as diagnostic indicators, markers of disease activity, and targets of therapeutic 
intervention. With such widespread and often overlapping properties, the challenge remains to 
establish how the individual characteristics of these cytokines contribute to disease progression 
and the co-morbidities presented by patients with complex chronic and malignant illnesses. This 
is especially pertinent to drug discovery, the development of combination-type interventions, 
and investigations that differentiate drug action. Despite much preclinical promise, very few 
efficacious therapies against members of this cytokine family have reached the clinic since the 
approval of tocilizumab in 2009. Although small molecule interventions (for example, JAK 
inhibitors) offer opportunities to target intracellular components of the gp130 cytokine receptor 
cassette, they also act on other cytokines that use common or alternative JAK–STAT signalling 
mechanisms. However, an improved understanding of the molecular interactions which 
underpin ligand–receptor assembly and cytokine receptor signalling has seen a rapidly 
expanding number of next-generation agonists and antagonists for gp130 or specific family 
members, including IL-6, IL-11, IL-27, LIF and OSM. As we acquire new insights into the 
mechanisms driving local pathology, and the contribution of the immune system to mental 
health, and physical and psychological wellbeing, the challenge is to establish whether these 
agents not only decrease disease activity, but also improve the overall quality of life of patients 
with chronic or debilitating disease. The coming decade therefore holds considerable promise, 
and offers exciting opportunities to explore the therapeutic application of cytokine-directed 
drugs in the clinical management of autoimmune, infectious and inflammatory diseases, as well 
as cancers.  
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 Glossary terms 
Janus kinase (JAK) – signal transducer and activator of transcription (STAT) pathway 
A cytokine receptor signalling mechanism used by certain cytokines to sense and interpret 
environmental cues during inflammation and immune homeostasis. 
 
Lymphokines 
A subset of cytokines that are released by lymphocytes.  
 
Adipokines 
A subset of cytokines secreted by adipose tissue, which are sometimes called adipocytokines. 
 
Myokines 
Cytokines produced and released by myocytes in response to muscle contraction. 
 
Pattern recognition receptors 
Innate sensors that detect bacteria, viruses, fungi and other endogenous ligands generally 
associated with tissue damage. 
 
Tumour microenvironment 
Cellular and non-cellular compartment associated with a tumour, comprising the extracellular 
matrix, surrounding blood and lymphatic vessels, immune (inflammatory) cells, fibroblasts, 
neuroendocrine cells and adipocytes.  
 
Cachexia 
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A wasting or weakening of the body due to chronic illness or cancer. 
 
Nanobody 
An engineered single-domain antibody. 
 
 Box Legends 
BOX 1: Signalling mechanisms for IL-6 family cytokines and links with physiological and 
disease processes  
Intracellular signalling mechanisms linked to the gp130 receptor system are triggered via 
activation of receptor-associated cytoplasmic tyrosine kinases (JAK1, JAK2 and TYK2). Activation 
of these proteins leads to distinct patterns of tyrosine phosphorylation and subsequent 
activation of the latent transcription factors signal transducer and activator of transcription 1 
(STAT1), STAT3 and, to a lesser extent, STAT5. Additional signalling mechanisms associated with 
cytokine activation of the gp130 receptor system include processes controlled through the 
tyrosine-protein phosphatase SHP2. The activation of this protein promotes signalling through 
the RAS–RAF pathway and the SRC–YAP–Notch pathway. Activation of the RAS–RAF cascade 
also regulates several downstream modifiers that include the phosphorylation of MAP kinases 
and the AKT and mTORC1 pathways, and activities associated with the transcription factors NF-
IL-6 (a C/EBP family member) and AP-1 (c-JUN and FOS). Other kinases with less defined 
involvements with this receptor system include SAK, HCK, FES, BTK and TEC16. Each of these 
signal transduction mechanisms control various biological processes as indicated. The heatmap 
depicted in the right-hand panel details how individual IL-6 cytokine family members contribute 
to specific physiological and immunological processes, and emphasizes their relative importance 
in certain disease settings (depicted below the blue line). 
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BOX 2: IL-6 family cytokines as regulators of metabolic processes  
Members of the IL-6 cytokine family perform integral roles in health and disease, and their 
capacity to influence the maintenance of immune homeostasis and wellbeing can occur via 
regulation of various metabolic processes. The depicted heatmap summarizes the relative 
contribution of individual members of the IL-6 cytokine family to metabolism, and emphasizes 
the types of metabolic processes they affect. Certain family members, such as IL-6 and OSM, 
elicit these effects in various stromal tissue compartments (for example, muscle, liver, bone, 
brain) and inflammatory cells (for example, lymphocytes, macrophages)246-248. On the other 
hand, IL-27 displays a more restricted activity profile on select immune cell types, where it 
controls the expression of enzymes responsible for oxysterol generation in effector and 
regulatory CD4+ T cells249. Importantly, several of these associations with metabolism have been 
identified through clinical observations in patients receiving biological drugs. For example, 
hypoferremia is a common response to systemic infection, and patients with autoimmune 
conditions, such as rheumatoid arthritis, frequently suffer from inflammatory anaemia250. Here, 
biological drugs against IL-6 (for example, tocilizumab) combat the development of anaemia and 
inhibit the hepatic-derived generation of hepcidin and haptoglobin251,252. These latter responses 
are also associated with OSM and LIF253. Further roles for IL-6 in metabolic processes have been 
identified from Il6-/- mice which develop mature onset obesity, hypertriglyceridemia and glucose 
intolerance, and patients on tocilizumab experience changes in serum cholesterol and 
triglyceride levels, along with increases in body weight254-256. The control of adipogenesis and 
lipolysis is also attributed to other IL-6 family cytokines, and these are reviewed elsewhere257-259. 
For instance, CNTF treatment in mice reduced adiposity and body weight, and improved various 
parameters of diabetes and hepatic steatosis, a finding that led to the development of 
recombinant CNTF therapy (axokine), which suppressed appetite, increased energy expenditure 
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and caused sustained weight loss in humans260-262. Consistent with a role for IL-6 family 
cytokines in regulating energy and glucose metabolism, acute infusion of IL-6 in mice enhanced 
glucose uptake and fatty acid oxidation in skeletal muscle associated with improved insulin 
sensitivity, and protection from diet-induced obesity263. Here, IL-6 released from contracting 
muscle drives the production of glucagon-like peptide-1 (GLP-1) within the gut and pancreas, 
and contributes to the maintenance of glucose homeostasis through the GLP-1 control of insulin 
secretion264. An important aspect of these metabolic-associated outcomes regulated by IL-6 
family members is their link with alterations in mitochondrial activity. Here, IL-6, OSM, CT1, 
CNTF, and other family members influence several aspects of mitochondrial biology including 
changes in mitochondrial re-modelling because of cachexia, alterations in mitochondrial calcium 
mobilization and membrane potential, and the regulation of thermogenesis through regulation 
of uncoupling protein-1265-271.  
 
BOX 3: Cartoon depicting alternate forms of cytokine receptor signalling by the IL-6 family of 
cytokines  
Several members of the IL-6 family adopt alternative modes of cellular activation via gp130. For 
example, IL-6 classical cytokine receptor signalling transduced via a gp130 homodimer is 
facilitated by membrane-bound forms of IL-6Rα and gp130 (for schematic purposes, only one 
gp130 molecule is shown). Soluble forms of the cognate non-signalling receptor-α subunits for 
IL-6, IL-11 and CNTF are readily detected in serum. These soluble receptors retain cytokine-
binding kinetics and form receptor-ligand complexes that activate cells through binding 
interactions with cell-associated gp130. Cytokine binding to soluble receptors also enhances the 
circulating half-life of the cytokine and offers protection from proteolytic degradation38. These 
forms of cellular activation are termed cytokine trans-signalling, and provide a mechanism to 
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broaden the types of cells that are responsive to IL-6, IL-11 or CNTF2. Recent evidence has 
identified another form of receptor engagement termed IL-6 trans-presentation272. Here, IL-6 
bound to membrane-bound IL-6Rα is displayed on the surface of cells (for example, specialized 
dendritic cells) and presented to gp130 expressed on a nearby cell type (for example, a 
lymphocyte) to elicit signalling via a gp130 homodimer (for schematic purposes, only one gp130 
molecule is shown). These additional forms of cytokine receptor signalling contribute to the 
regulation of innate and adaptive immunity, and direct responses in target cells that lack 
specific receptors for these cytokines. Also shown are the numerous cellular processes 
associated with each of these signalling modes.  
 
 
 
 Figure Legends 
Figure 1: Cytokine receptor usage by the IL-6 family of cytokines  
(a) Members of the IL-6 cytokine family share a common ancestral link to an innate immune 
sensing mechanism found in Drosophila melanogaster. This system consists of unpaired-3 (IL-6-
like), domeless (gp130-like), hopscotch (Drosophila homolog of mammalian JAK) and stat92E 
marelle (Drosophila homolog of STAT, also referred to as marelle). (b, c) In mammals, all 
cytokines within the family activate cells through receptor complexes that contain the signal 
transducing receptor β subunit gp130. Three distinct forms of cytokine receptor arrangements 
are utilized by these cytokines. In (b), receptor complexes for IL-6 and IL-11 contain a cognate 
non-signalling receptor-α subunit and gp130 (termed a gp130 homodimer receptor complex), 
with gp130 existing as a homodimer to elicit signalling. Based on the proposed structural 
arrangement of the IL-6 receptor, a functioning receptor is composed of an IL-6–IL-6R–gp130 
complex that is clustered into a dimer structure16,245. In contrast, in (c) receptor complexes for 
LIF, CT-1, OSM and IL-27 comprise gp130 and a second receptor subunit, which contain 
structural features similar to gp130 (termed a gp130 heterodimer receptor complex). These 
include the LIF receptor-β (LIFRβ), OSM receptor-β (OSMRβ) and IL-27Rα (also referred to as 
WSX-1 or TCCR). The receptor for CNTF and CLCF1 is comprised of three individual receptor 
subunits formed between CNTF receptor-α (CNTFR), LIFRβ and gp130. Currently, IL-31 remains 
the only exception to this ‘gp130 rule’ and the IL-31 receptor consists of IL-31Rα and OSMRβ. 
These alternate receptors provide cytokine specificity and couple directly to signal transduction 
pathways required for cellular activation (BOX 1).  
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Figure 2: The intrinsic and extrinsic properties of IL-6 family cytokines in cancer  
The figure provides an overview of the cellular processes that are regulated by members of the 
IL-6 cytokine family, along with the predominant activation of STAT3, during tumorigenesis, 
tumour metastasis, and in the control of the tumour microenvironment and cancer 
inflammation. Cytokines with specific links to the control of these activities are shown. Note 
that processes associated with tumour metastasis can also contribute to the overall architecture 
of the tumour microenvironment and support activities linked with the development of cancer 
inflammation.  
 
Figure 3: The IL-6 cytokine family as therapeutic targets  
 
Members of the IL-6 cytokine family are drug targets for the treatment of infection, 
inflammation, autoimmunity and cancer. Classes of drugs include monoclonal antibodies and 
recombinant protein modalities for specific cytokines or cytokine receptors (shown in top 
target), and small molecule interventions that modulate receptor signalling activity or 
intracellular mechanisms linked to gp130 or JAK–STAT signalling (shown in bottom target). A 
cartoon depicting a representative cytokine–cytokine receptor complex of the IL-6 cytokine 
family is shown. Examples of these drug classes are depicted on the zoned targets. Each target is 
colour coded to reflect the stage of clinical development (as indicated in the key, bottom left), 
and the current status of an individual drug within this pipeline is represented by an annotated 
dot (right-hand keys). Drugs displaying related modes-of-action or common targets are 
accordingly coloured. Abbreviations for cytokine-cytokine receptor therapies: ciliary 
neurotrophic factor (CNTF), clazakizumab (CLZ), VHH6 (VHH), EBI-031 (EBI), GSK315234 (GSK), 
interleukin-11 (IL11), interleukin-27 (IL27), p28 subunit of interleukin-27 (p28), leukemia 
inhibitory factor (LIF), NI-1201 (NI), olamkicept (OLM), olokizumab (OKZ), sarilumab (SAR), 
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sirukumab (SIR), siltuximab (STX), tocilizumab (TCZ), vobarilizumab (VOB). Abbreviations for 
small molecule interventions: AZD9150 (AZD), baricitinib (BAR), capsaicin (CAP), cisplatin 
derivatives (CPA-1, CPA-7), CpG-Stat3-siRNA (CpG-STAT3), curcumin (CUR), dasatinib (DAS), 
filgotinib (FLG), LMT-28 (LMT), madindoline-A (MAD), oclacitinib (OCL), regulator of cartilage 
growth and differentiation-423 (RCGD), ruxolitinib (RUX), SC144 (SC), tofacitinib (TOF). 
 
 
 
 
